{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:36Z","timestamp":1790395476728,"version":"4.1.0"},"reference-count":18,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:p>Fabry disease is a rare X-linked recessive lysosomal storage disease. Multiple mutations of the GLA gene lead to a deficient or absent activity of the lysosomal enzyme \u03b1-galactosidase A, resulting in progressive glycotriaosylceramide accumulation in many organs. Low \u03b1-galactosidase A activity and mutations in the GLA gene confirm the diagnosis. Clinical signs are multisystemic, heterogeneous, and progressive. Renal, cardiac, and neurovascular involvements are the main life-threatening complications, highlighting the importance of an early initiation of enzyme replacement therapy improving long-term outcome. Fabry nephropathy lesions are characterized by a cell vacuolization of glomeruli, tubules, interstitium, and arteries and by ultrastructural myelin bodies. The main histologic differential diagnoses are toxicity of lysosomal inhibitors and other renal lipidoses. Renal biopsies are not necessary for diagnosis but have an important role in the evaluation of disease evolution and treatment efficiency, which is a major challenge for improving outcome and quality of life.<\/jats:p>","DOI":"10.5858\/arpa.2016-0418-rs","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T11:45:39Z","timestamp":1501069539000},"page":"1127-1131","source":"Crossref","is-referenced-by-count":19,"title":["Fabry Nephropathy"],"prefix":"10.5858","volume":"141","author":[{"given":"Prudence","family":"Colpart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"F\u00e9lix","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University Hospital of Besan\u00e7on, CHRU, Besan\u00e7on, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"issue":"8","key":"2020081300190819600_i1543-2165-141-8-1127-b01","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS\u2013Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"issue":"2","key":"2020081300190819600_i1543-2165-141-8-1127-b02","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry Disease: structure of human \u03b1-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J Mol Biol"},{"key":"2020081300190819600_i1543-2165-141-8-1127-b03","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2020081300190819600_i1543-2165-141-8-1127-b04","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2020081300190819600_i1543-2165-141-8-1127-b05","first-page":"310","article-title":"Renal involvement in Anderson-Fabry disease","volume":"16","author":"Sessa","year":"2003","journal-title":"J Nephrol"},{"issue":"3","key":"2020081300190819600_i1543-2165-141-8-1127-b06","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"issue":"2","key":"2020081300190819600_i1543-2165-141-8-1127-b07","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10545-010-9261-9","article-title":"Toward a consensus in the laboratory diagnostics of Fabry disease: recommendations of a European expert group","volume":"34","author":"Gal","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"2020081300190819600_i1543-2165-141-8-1127-b08","doi-asserted-by":"crossref","first-page":"75","DOI":"10.55418\/1881041964-04","article-title":"Hereditary nephropathies","author":"D'Agati","year":"2005","journal-title":"AFIP Atlas of Nontumor Pathology Non-Neoplastic Kidney Diseases. 1st ed"},{"key":"2020081300190819600_i1543-2165-141-8-1127-b09","first-page":"350","article-title":"Fabry disease","author":"Colvin","year":"2011","journal-title":"Diagnostic Pathology: Kidney Diseases. 2nd ed"},{"issue":"10","key":"2020081300190819600_i1543-2165-141-8-1127-b10","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/modpathol.3800634","article-title":"Fabry disease: a morphologic study of 11 cases","volume":"19","author":"Fischer","year":"2006","journal-title":"Mod Pathol"},{"key":"2020081300190819600_i1543-2165-141-8-1127-b11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/8904_2011_14","article-title":"Foot process effacement with normal urinalysis in classic Fabry Disease","volume":"1","author":"Kanai","year":"2011","journal-title":"JIMD Rep"},{"issue":"6","key":"2020081300190819600_i1543-2165-141-8-1127-b12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Podocyte injury and GL-3 accumulation are progressive in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int"},{"issue":"7","key":"2020081300190819600_i1543-2165-141-8-1127-b13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0046-8177(87)80238-1","article-title":"Renal lipidoses: a review","volume":"18","author":"Faraggiana","year":"1987","journal-title":"Hum Pathol"},{"key":"2020081300190819600_i1543-2165-141-8-1127-b14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fendo.2014.00127","article-title":"Podocyte pathology and nephropathy\u2014sphingolipids in glomerular diseases","volume":"5","author":"Merscher","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2020081300190819600_i1543-2165-141-8-1127-b15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/modpathol.3800344","article-title":"Chloroquine induced lipidosis mimicking Fabry disease","volume":"18","author":"Albay","year":"2005","journal-title":"Mod Pathol"},{"issue":"6","key":"2020081300190819600_i1543-2165-141-8-1127-b16","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"issue":"7","key":"2020081300190819600_i1543-2165-141-8-1127-b17","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/ndt\/gfp528","article-title":"Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)","volume":"25","author":"Fogo","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2020081300190819600_i1543-2165-141-8-1127-b18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.nephro.2012.03.007","article-title":"La biopsie r\u00e9nale dans la maladie de Fabry: \u00e9tude multicentrique fran\u00e7aise","volume":"8","author":"No\u00ebl","year":"2012","journal-title":"Nephrol Ther"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/141\/8\/1127\/1447086\/arpa_2016-0418-rs.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/141\/8\/1127\/1447086\/arpa_2016-0418-rs.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:38:00Z","timestamp":1764790680000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/141\/8\/article-p1127.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,1]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2016-0418-rs","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,1]]}}}